“Sarclisa Phase 3 Trial Achieves Primary Endpoint: Progression-Free Survival in Myeloma Patients”

By | December 7, 2023
0 Comment

SEE AMAZON.COM DEALS FOR TODAY

SHOP NOW

The Phase 3 trial of Sarclisa (isatuximab) has achieved its primary endpoint of progression-free survival in newly diagnosed multiple myeloma patients who are not eligible for transplant. The news has impacted the stocks of UCO, USO, and SNYNF.

BREAKING NEWS: Sarclisa Phase 3 Trial Meets Primary Endpoint in Multiple Myeloma Study

You may also like to watch: Is US-NATO Prepared For A Potential Nuclear War With Russia - China And North Korea?

In a recent press release, $SNYNF announced that its drug Sarclisa (isatuximab) has successfully met the primary endpoint of progression-free survival in patients with newly diagnosed multiple myeloma who are not eligible for a transplant.

Multiple myeloma is a type of blood cancer that affects plasma cells in the bone marrow. It is a relatively rare condition, but it can be aggressive and difficult to treat. Transplantation is often considered the standard treatment for eligible patients, but not all individuals are suitable candidates for this procedure.

The Phase 3 trial for Sarclisa involved a group of patients who were newly diagnosed with multiple myeloma and ineligible for a transplant. The primary endpoint of the study was progression-free survival, which measures the length of time patients live without their disease progressing. The results of the trial showed that Sarclisa was effective in achieving this endpoint, indicating its potential as a treatment option for this specific patient population.

Sarclisa is an antibody that works by targeting a protein called CD38, which is found on the surface of myeloma cells. By binding to CD38, Sarclisa helps the body’s immune system recognize and destroy the cancer cells.

The news of Sarclisa’s success in the Phase 3 trial is significant for patients with newly diagnosed multiple myeloma who are not eligible for a transplant. It provides hope for improved treatment options and better outcomes for this particular group of individuals.

Further research and regulatory approvals will be necessary before Sarclisa can become widely available for this patient population. However, the positive results from the Phase 3 trial are a promising step forward in the fight against multiple myeloma..

Source

@marketwirenews said BREAKING NEWS: $SNYNF Press Release: Sarclisa (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant marketwirenews.com/news-releases/… $UCO $USO $SNYNF